POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS)
Clinical trials for POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) explained in plain language.
Never miss a new study
Get alerted when new POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) trials appear
Sign up with your email to follow new studies for POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental POTS drug targets racing heart in first human test
Symptom relief OngoingThis study tests a single dose of an experimental drug called REGN7544 in 82 people with Postural Orthostatic Tachycardia Syndrome (POTS). The goal is to see if the drug safely reduces the rapid heart rate that happens when standing up. Researchers will also check for side effect…
Matched conditions: POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Skin biopsies may reveal long COVID's hidden nerve damage
Knowledge-focused OngoingThis study looks at tiny nerve fibers in the skin of people with Long COVID, POTS, diabetic neuropathy, and those who had COVID-19 without lasting symptoms. By comparing skin samples, researchers hope to find unique patterns that help explain ongoing symptoms like pain and dizzin…
Matched conditions: POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS)
Sponsor: CND Life Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC